Alaunos Therapeutics, Inc. — Operating Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/67df41e6-e9c9-429f-90ef-5de9dc444bbd/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-4.2M | 2025-01-01 – 2025-12-31 | evidence 0001193125-26-134720 |
| FY 2024 | $-4.8M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-047758 |
| FY 2023 | $-34.3M | 2023-01-01 – 2023-12-31 | evidence 0000950170-24-038868 |
| FY 2022 | $-35.1M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-006377 |
| FY 2021 | $-77.5M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-004972 |
| FY 2020 | $-80.4M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-063387 |
| FY 2019 | $-57.9M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-058863 |
| FY 2018 | $-53.9M | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-063978 |
| FY 2017 | $-53.5M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-067077 |
| FY 2016 | $-165.3M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-046668 |
| FY 2015 | $-120.1M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-475875 |
| FY 2014 | $-43.5M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-065956 |
| FY 2013 | $-366.7M | 2003-09-10 – 2014-03-31 | evidence 0001193125-14-189905 |
| FY 2012 | $-322.8M | 2003-09-10 – 2013-03-31 | evidence 0001193125-13-204366 |
| FY 2011 | $-215.7M | 2003-09-10 – 2012-03-31 | evidence 0001144204-12-025871 |
| FY 2010 | $-24.5M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-012003 |
| FY 2009 | $-12.1M | 2009-01-01 – 2009-12-31 | evidence 0001144204-12-012003 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Alaunos Therapeutics, Inc. — all facts · Revenue · Net Income